pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
BioNTech SE is a pharma organization headquartered in Mainz, DE. Primary therapeutic focus areas include Non-small Cell Lung Cancer, Solid Tumors, Melanoma (Stage III and IV), Endometrial cancer, Resected (R0 or R1) panc
An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE HQ
2008 Founded
5,119 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
BNT327-05
Phase 3 · small molecule · First line triple-negative breast cancer (TNBC)
BNT327-05 for First line triple-negative breast cancer (TNBC) is a Phase 3 program (small_molecule) at BioNTech SE with 1 ClinicalTrials.gov record(s).
Internal code BNT327-05
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BioNTech SE
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- First line triple-negative breast cancer (TNBC)
- Status
- active
- Trials
- 1